Company intelligence / Profile preview

Breakthru Medicine

Phoenix, Arizona, United States

Ownership: Private
Development stage: Other

Overview

Breakthru Medicine is a biotechnology company that emerged from stealth in January 2026 with a $60 million Series A financing. The company focuses on developing disruptive oncology therapies using a multi-modality approach that includes small molecules, molecular glues, and next-generation antibody-drug conjugate (ADC) payloads. Led by industry veterans, the company utilizes a tumor-agnostic targeting strategy to address high unmet medical needs in cancer.

Therapeutic areas: Oncology
Modalities: Small moleculeMolecular glue therapyAntibody-drug conjugate
Industry: Biotech

Beyond the preview

Go deeper on Breakthru Medicine.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Breakthru Medicine.

Explore the full profile